OncoMatch/Clinical Trials/NCT06389799
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Is NCT06389799 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pemigatinib and Retifanlimab for dedifferentiated liposarcoma.
Treatment: Pemigatinib · Retifanlimab — Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options. Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in previous studies. Effect of immunotherapy can be improved by combining it with other types of tumor drugs. Medicines that inhibit signaling via the FGF receptor, so-called FGFR inhibitors, have shown a tumor-slowing effect in DDLPS in early studies. FGFR inhibitors can also induce changes that make the tumor more available to treatment with immunotherapy. The study aims to investigate whether the combination of an FGFR inhibitor, pemigatinib, with a PD-1 inhibitor, retifanlimab can provide a tumor-slowing effect in patients with advanced DDLPS who have progressed on first-line treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Sarcoma
Biomarker criteria
Required: MDM2 amplification
MDM2 amplification as demonstrated by fluorescence in situ hybridization, polymerase chain reaction (PCR) or sequencing-based methods must be available.
Required: MDM2 overexpression
positive MDM2 immunohistochemistry
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic treatment
Disease relapse or radiological progression, as determined by the Investigator, within the last 6 months after at least one line of systemic treatment.
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Cannot have received: FGFR inhibitor
Has received prior therapy with a selective FGFR inhibitor.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06389799 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, FGFR inhibitor disqualifies patients from enrollment.
Does this trial require MDM2?
Yes, MDM2 amplification is a required biomarker for enrollment.
Does this trial require MDM2?
Yes, MDM2 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages